Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

ABCT information sessions scheduled

Accelerator for Biosciences in Connecticut, ABCT, is a competitive entry, 6-month long program designed for entrepreneurial research students and faculty, MBA’s and MD’s interested in...

| By Kelley Gipson

Cybrexa names John Houston to board of directors

Cybrexa Therapeutics has appointed John Houston, PhD, to its board of directors. Dr. Houston brings more than 30 years of biotech and pharma drug development and...

| By Kelley Gipson

BioCT Launches New England Edge Purchasing Program

Introducing New England Edge, our new, exclusive purchasing program powered by MassBio. As a dedicated supporter of Connecticut’s bioscience industry, BioCT is constantly evaluating the...

| By Kelley Gipson

Europe approves Alexion SOLIRIS® treatment

Alexion Pharmaceuticals reports that the European Commission has approved the extension of the current marketing authorization of SOLIRIS® (eculizumab) to include the treatment of neuromyelitis optica...

| By Kelley Gipson

BioXcel gains orphan drug status re leukemia

BioXcel Therapeutics reports that the FDA has granted Orphan Drug Designation for BXCL701, an investigational orally-available systemic innate immunity activator with dual mechanisms of action,...

| By Kelley Gipson

SpringWorks wins BTD re desmoid tumors

SpringWorks Therapeutics reports that the FDA has granted Breakthrough Therapy Designation for nirogacestat, an oral, selective, small molecule, gamma-secretase inhibitor, for the treatment of adult patients...

| By Kelley Gipson

Yale Expo attracts students who mean business

Tuesday’s Yale Entrepreneurship & Innovation Expo brought together Yale’s many entrepreneurial organizations and clubs for a three-hour meet-and-greet with one another and members of the...

| By Kelley Gipson

Tangen Biosciences inaugurates Branford facility

Connecticut Governor Ned Lamont, U.S. Sen. Richard Blumenthal, and other luminaries were on hand recently when Tangen Biosciences unveiled its new 16,300-square-foot facility at 20 Commerce Drive...

| By Kelley Gipson

Arvinas starts patient dosing of protein degrader

Arvinas has announced the initiation of patient dosing in its second clinical program. The Phase 1 clinical trial of ARV-471, an oral estrogen receptor (ER)-targeting...

| By Kelley Gipson

Yale scientists zero in on atomic tumor formation

Certain types of bacteria are capable of causing colorectal cancers, indicating that a sub-set of these cancers could be the result of infectious disease. There...